Anvatabart opadotin

A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

Phase 1

Completed

Locations: 🇺🇸
USC Norris Cancer Hospital, Los Angeles, California, United States
🇺🇸
UCLA Hematology-Oncology, Santa Monica, California, United States
🇦🇺
Monash Health, Clayton, Victoria, Australia

Phase 1

Terminated

Locations: 🇦🇺
Monash Medical Centre, Clayton, Victoria, Australia
🇳🇿
Wellington Hospital, Newtown, Wellington, New Zealand
🇦🇺
Mater Adult Hospital, South Brisbane, Queensland, Australia

Phase 2

Recruiting

Conditions: HER2-negative Breast Cancer
Hormone Receptor Positive Tumor
Angiosarcoma
TNBC - Triple-Negative Breast Cancer
Breast Neoplasms
Breast Tumors
HER2-positive Breast Cancer
Hormone Receptor Negative Tumor
Breast Cancer
Early-stage Breast Cancer

Interventions: Drug: Cemiplimab
Drug: Cemiplimab plus REGN3767
Drug: Sarilumab + Cemiplimab + Paclitaxel
Drug: Tucatinib plus trastuzumab and pertuzumab
Drug: ARV-471 + Letrozole
Drug: ARV-471 + Abemaciclib
Drug: Endoxifen + Abemaciclib
Drug: Standard Therapy
Drug: AMG 386 with or without Trastuzumab
Drug: AMG 479 (Ganitumab) plus Metformin
Drug: MK-2206 with or without Trastuzumab
Drug: T-DM1 and Pertuzumab
Drug: Pertuzumab and Trastuzumab
Drug: Ganetespib
Drug: ABT-888
Drug: Neratinib
Drug: PLX3397
Drug: Pembrolizumab - 4 cycle
Drug: Talazoparib plus Irinotecan
Drug: Patritumab and Trastuzumab
Drug: Pembrolizumab - 8 cycle
Drug: Durvalumab plus Olaparib
Drug: SD-101 + Pembrolizumab
Drug: Trilaciclib with or without trastuzumab + pertuzumab
Drug: SYD985 ([vic-]trastuzumab duocarmazine)
Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab
Drug: Dan222 + Niraparib
Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab
Drug: Amcenestrant
Drug: Amcenestrant + Abemaciclib
Drug: Amcenestrant + Letrozole
Drug: ARX788
Drug: ARX788 + Cemiplimab
Drug: VV1 + Cemiplimab
Drug: Datopotamab deruxtecan
Drug: Datopotamab deruxtecan + Durvalumab
Drug: Lasofoxifene
Drug: Z-endoxifen
Drug: ARV-471
Drug: Rilvegostomig + TDXd
Drug: SGN-LIV1A
Drug: Zanidatamab
Drug: AMG 386 and Trastuzumab

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
University of Texas, Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
University of Kansas, Westwood, Kansas, United States

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.